Uy Ear, an analyst from Mizuho Securities, maintained the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $8.00.
Uy Ear of Mizuho Securities has given Arcutis Biotherapeutics a Buy rating, influenced by a combination of positive factors surrounding the company’s recent product launch. The early launch of Zoryve foam for treating seborrheic dermatitis, which was slightly ahead of the market’s expectations, represents a significant development for Arcutis. The strategic procurement of formulary coverage from all three national Pharmacy Benefit Managers (PBMs) – Express Scripts, CVS Caremark, and Optum Rx – is seen as a strong indicator for potential market penetration and successful product uptake.
Moreover, the foam formulation of Zoryve presents several key advantages over the previously launched cream version, which bodes well for its adoption. These advantages include the comprehensive formulary coverage from the outset, inclusion in key Electronic Medical Record (EMR) platforms, an already established relationship with healthcare providers from the psoriasis cream launch, a familiar co-pay card system for pharmacies, and the lack of direct branded competition at the time of launch. These factors collectively contribute to Uy Ear’s optimistic outlook for Arcutis Biotherapeutics and the rationale behind the Buy rating.
According to TipRanks, Ear is a 3-star analyst with an average return of 4.4% and a 39.53% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Neurocrine.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcutis Biotherapeutics (ARQT) Company Description:
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Read More on ARQT:
- Arcutis Biotherapeutics announces launch of ZORYVE topical foam in U.S.
- Arcutis Biotherapeutics announces new individual patient response data
- Arcutis Biotherapeutics announces new subgroup analysis from STRATUM study
- Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
- ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
